source
- BMS leverages Celgene merger to revive neuroscience pipeline amid delayed readoutsBristol Myers Squibb, long recognized for its oncology work, is re‑investing in neurological and psychiatric disease programs, a move rooted in assets gained from its 2019 $74 billion Celgene merge…
- Radiopharmaceutical experts urge pharma to adopt bolder dosing despite safety concernsLouise Emmett and a group of radiopharmaceutical specialists argue that these modern radiation‑based drugs could dramatically improve cancer outcomes if used more aggressively. They say the therapi…